Skip to main content

Advertisement

Log in

Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844–54.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis. 2010;55 Suppl 3:S1–13.

    Article  PubMed  Google Scholar 

  3. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149:578–86.

    Article  CAS  PubMed  Google Scholar 

  4. Gertz MA. Managing tumor lysis syndrome in 2010. Leuk Lymphoma. 2010;51:179–80.

    Article  PubMed  Google Scholar 

  5. Gemici C. Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol). 2006;18:773–80.

    Article  CAS  Google Scholar 

  6. Ferraro D, Zalcberg J. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy. Ther Adv Med Oncol. 2014;6(5):222–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12.

    Article  CAS  PubMed  Google Scholar 

  8. Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, Morra E, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica. 2008;93(12):1877–85.

    Article  PubMed  Google Scholar 

  9. Frestad D, Perner A, Pedersen UG. Acute onset and rapid progression of multiple organ failure in a young adult with undiagnosed disseminated colonic adenocarcinoma. BMJ Case Rep. 2014;24:2014.

    Google Scholar 

  10. Nikolic-Tomasevic Z, Jelic S, Popov I, Radosavljevic D. Colorectal cancer: dilemmas regarding patient selection and toxicity prediction. J Chemother. 2000;12:244–51.

    Article  CAS  PubMed  Google Scholar 

  11. Boisseau M, Bugat R, Mahjoubi M. Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11). Eur J Cancer. 1996;32:737–8.

    Article  Google Scholar 

  12. Kim HD, Ha KS, Woo IS, Jung YH, Han CW, Kim TJ. Tumor lysis syndrome in a patient with metastatic colon cancer after treatment with 5-fluorouracil/leucovorin and oxaliplatin: case report and literature review. Cancer Res Treat. 2014;46(2):204–7.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Hentrich M, Schiel X, Scheidt B, Reitmeier M, Hoffmann U, Lutz L. Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer. Acta Oncol. 2008;47:155–6.

    Article  CAS  PubMed  Google Scholar 

  14. Krishnan G, D’Silva K, Al-Janadi A. Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma. J Clin Oncol. 2008;26:2406–8.

    Article  PubMed  Google Scholar 

  15. Oztop I, Demirkan B, Yaren A, Tarhan O, Sengul B, Ulukus C, et al. Rapid tumor lysis syndrome in a patient with metastatic colon cancer as a complication of treatment with 5-fluorouracil/leucoverin and irinotecan. Tumori. 2004;90:514–6.

    PubMed  Google Scholar 

  16. Vaisban E, Braester A, Mosenzon O, Kolin M, Horn Y. Spontaneous tumor lysis syndrome in solid tumors: really a rare condition? Am J Med Sci. 2003;325(1):38–40.

    Article  PubMed  Google Scholar 

  17. Patterson DJ, Dew EW, Gyorkey F, Graham DY. Niacin hepatitis. South Med J. 1983;76:239–41.

    Article  CAS  PubMed  Google Scholar 

  18. Pye E, Northcote RJ, Cobbe SM. Acute hepatitis after parenteral amiodarone administration. Br Heart J. 1988;59:690–1.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Huang WS, Yang CH. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol. 2009;15(35):4464–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Shiozawa K, Watanabe M, Takenaka H, Nagai H, Ishii K, Sakai K, et al. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report. Hepatogastroenterology. 2010;57(101):688–90.

    CAS  PubMed  Google Scholar 

Download references

Conflicts of Interest

The authors report no conflict of interests.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bilal Farooqi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Farooqi, B., Simmons, J. & Hao, Z. Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib. J Gastrointest Canc 46, 314–316 (2015). https://doi.org/10.1007/s12029-015-9711-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-015-9711-6

Keywords

Navigation